Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evolus, Inc. - Common Stock
(NQ:
EOLS
)
7.660
+0.290 (+3.93%)
Delayed Quote
Updated: 1:21 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
August 24, 2022
From
Evolus
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
August 05, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 02, 2022
Via
Benzinga
Evolus Reports Second Quarter 2022 Results and Provides Business Update
August 02, 2022
From
Evolus
Via
Business Wire
Needham Is Bullish On This Botox Equivalent Aesthetics Company
↗
June 24, 2022
Via
Benzinga
Recap: Evolus Q4 Earnings
↗
March 03, 2022
Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed...
Via
Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
↗
August 03, 2022
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks.
Via
Benzinga
Recap: Evolus Q2 Earnings
↗
August 02, 2022
Evolus (NASDAQ:EOLS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
A Preview Of Evolus's Earnings
↗
March 02, 2022
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
Evolus's Earnings: A Preview
↗
August 01, 2022
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an...
Via
Benzinga
Evolus to Report Second Quarter 2022 Results and Provide Business Update
July 19, 2022
From
Evolus
Via
Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
July 19, 2022
From
Evolus
Via
Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
July 12, 2022
From
Evolus
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
↗
June 23, 2022
Upgrades
Via
Benzinga
Evolus's Return On Capital Employed Overview
↗
June 10, 2022
According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million.
Via
Benzinga
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
June 02, 2022
From
Evolus
Via
Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
May 18, 2022
From
Evolus
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
↗
May 13, 2022
Upgrades
Via
Benzinga
Evolus to Participate in the H.C. Wainwright Global Investment Conference
May 11, 2022
From
Evolus
Via
Business Wire
Evolus: Q1 Earnings Insights
↗
May 10, 2022
Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%,...
Via
Benzinga
Evolus Reports First Quarter 2022 Results and Provides Business Update
May 10, 2022
From
Evolus
Via
Business Wire
Evolus to Report First Quarter 2022 Results and Provide Business Update
April 26, 2022
From
Evolus
Via
Business Wire
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
March 31, 2022
From
Evolus
Via
Business Wire
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 29, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Evolus's Return On Capital Employed Insights
↗
March 09, 2022
According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million...
Via
Benzinga
Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook
↗
March 04, 2022
Evolus Inc's (NASDAQ: EOLS) Q4 FY21 sales increased 68% Y/Y to $34.7 million in line with interim results, beating the consensus of $33.99 million, driven...
Via
Benzinga
Earnings Scheduled For March 3, 2022
↗
March 03, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...
Via
Benzinga
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
February 17, 2022
From
Evolus
Via
Business Wire
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
February 08, 2022
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
February 07, 2022
Gainers Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 132.3% to $7.55 during Monday's regular session. The current volume of 17.0 million shares is 2307.5% of...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
